Does Use of Topical Lidocaine in EGD Reduce Amount of IV Midazolam and Fentanyl Required and Shorten Recovery Time

NCT ID: NCT02620501

Last Updated: 2015-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

106 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-31

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients will be randomized to a placebo or study group who will receive topical lidocaine prior to EGD. Amount of medication used, recovery time, patient/endoscopist satisfaction will then be assessed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be a double blinded randomized placebo controlled trial

Patients between 18 and 89 years old who are scheduled for EGD may be eligible to enroll in the study. Potential subjects will be sought through referral by their treating attending and fellow gastroenterologist, who will be apprised of the inclusion and exclusion criteria. Patients possibly meeting inclusive and exclusive criteria will be approached and discussed the study further with the investigators. Those expressing a desire to participate in the study will be given written informed consent prior to participation. The investigators will enroll patients into the study with a goal of at least 53 patients in each group which is the number of patients our statistician recommended to appropriately power our study.

Patients who consent to enroll in the study will be randomized into 2 groups. Group 1: Swish and swallow 10ml of 2% lidocaine solution Group 2: Swish and swallow 10ml of 0.45% sodium chloride solution

The patients will then undergo endoscopy for the indication identified in their clinic appointment. Following the procedure, patients will be taken to the recovery area and recovered per clinic protocol. The endoscopist will complete a satisfaction questionnaire. The day following the procedure a nurse will call to check for post-operative complications per clinic protocol. The day following, an investigator will also call to perform a patient satisfaction survey..

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dysphagia GERD Abdominal Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Patients will receive 10cc of 1/2 normal saline to gargle prior to EGD

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

0.45% Normal Saline

Experimental

Patients will receive 10cc of 2% topical lidocaine to gargle prior to EGD

Group Type EXPERIMENTAL

Lidocaine

Intervention Type DRUG

topical lidocaine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine

topical lidocaine

Intervention Type DRUG

Placebo

0.45% Normal Saline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* EGD alone performed by staff gastroenterologist as an outpatient
* Between the age of 18 and 89
* Not requiring anesthesia support or use of medications other than fentanyl and midazolam

Exclusion Criteria

* Prior history of head and neck surgery
* Known hypersensitivity to local anesthetics, the amide type or any components of the topical lidocaine
* Patients having interventions other than polypectomy performed
* Pregnant or breast feeding females
* Patients with severe liver impairment
* Known hypersensitivity to benzodiazepine or fentanyl
Minimum Eligible Age

18 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Brooke Army Medical Center

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Adam Tritsch

Gastroenterology Fellow

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Adam M Tritsch, MD

Role: PRINCIPAL_INVESTIGATOR

Brooke Army Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Brooke Army Medical Center

Fort Sam Houston, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Adam M Tritsch, MD

Role: CONTACT

210-916-4367

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Adam M Tritsch, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Davis DE, Jones MP, Kubik CM. Topical pharyngeal anesthesia does not improve upper gastrointestinal endoscopy in conscious sedated patients. Am J Gastroenterol. 1999 Jul;94(7):1853-6. doi: 10.1111/j.1572-0241.1999.01217.x.

Reference Type BACKGROUND
PMID: 10406247 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BrookeAMC

Identifier Type: -

Identifier Source: org_study_id